Dr. Schofield received his Ph.D. in biochemistry from the Queensland Institute of Medical Research in Brisbane, Australia, in 1986. From 1986 to 1988, he conducted postdoctoral research in the Department of Medical and Molecular Parasitology of the New York University School of Medicine in the United States, where he subsequently held the position of junior faculty instructor until 1990. From 1990 to 1994, he was staff scientist at the Medical Research Council National Institute for Medical Research in London. In 2002, he shared in the Robert P. Goldberg Grand Prize from the Massachusetts Institute of Technology; in 2003 and 2006, he received the National Health and Medical Research Council (NHMRC) Support Enhancement Award from the Australian government. He is a cofounder of Ancora Pharmaceuticals, Inc., in Boston, Massachusetts. He is currently an NHMRC Principal Research Fellow, a Bio21 Industry Fellow, and head of the Laboratory of Malaria Immunology at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia. This is his second HHMI international research scholar award.

Louis Schofield is investigating the role of innate immunity and the parasite toxin in susceptibility and resistance to severe malaria. He hopes that determining the role of the toxin and innate responses in disease and the role of antitoxin antibodies and counter-regulatory mechanisms in clinical immunity to malaria will provide a rational basis for the development of interventions that prevent malaria fatalities.